Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $8.00.

Several research analysts have weighed in on SANA shares. HC Wainwright lowered their price target on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, March 4th. Bank of America raised their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Zacks Research lowered shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $12.00 price target on shares of Sana Biotechnology in a research note on Friday, March 13th.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $3.12 on Tuesday. The business has a 50-day moving average of $4.01 and a 200-day moving average of $4.15. The stock has a market capitalization of $832.63 million, a price-to-earnings ratio of -3.22 and a beta of 1.96. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, sell-side analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Sana Biotechnology by 4.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock worth $188,000 after acquiring an additional 2,023 shares during the last quarter. Xponance LLC lifted its holdings in Sana Biotechnology by 25.6% during the 4th quarter. Xponance LLC now owns 13,068 shares of the company’s stock valued at $53,000 after purchasing an additional 2,662 shares during the last quarter. Creative Planning lifted its holdings in Sana Biotechnology by 5.3% during the 3rd quarter. Creative Planning now owns 54,177 shares of the company’s stock valued at $192,000 after purchasing an additional 2,719 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Sana Biotechnology by 29.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock worth $53,000 after purchasing an additional 2,943 shares during the period. Finally, Savant Capital LLC boosted its position in Sana Biotechnology by 5.6% during the third quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock worth $236,000 after purchasing an additional 3,500 shares during the period. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.